David Misdrahi
Overview
Explore the profile of David Misdrahi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gerentes M, Lajnef M, Szoke A, Aouizerate B, Berna F, Clery M, et al.
Drug Saf
. 2025 Mar;
PMID: 40088341
Background: The life expectancy of patients with schizophrenia is reduced, partly due to cardiovascular diseases. Antipsychotics are associated with QT interval prolongation, which is a risk factor for arrhythmia and...
2.
Barbosa S, Tamouza R, Leboyer M, Aouizerate B, Andrieu C, Andre M, et al.
Prog Neuropsychopharmacol Biol Psychiatry
. 2025 Mar;
137:111304.
PMID: 40023308
Background: Schizophrenia (SZ) commonly manifests through multiple relapses, each impeding the path to recovery and incurring personal and societal costs. Despite the identification of various risk factors associated to the...
3.
Chirokoff V, Tessier A, Serre F, Dupuy M, Auriacombe M, Chanraud S, et al.
Br J Clin Psychol
. 2025 Feb;
PMID: 39960195
Background: Medication non-adherence is a leading cause of treatment failure in psychiatric populations. However, current studies highlight the lack of methodological guidance on medication assessments. Ecological Momentary Assessment (EMA), using...
4.
Vidal N, Roux P, Urbach M, Belmonte C, Boyer L, Capdevielle D, et al.
Front Pharmacol
. 2024 Jun;
15:1403093.
PMID: 38933674
Aim: The anticholinergic properties of medications are associated with poorer cognitive performance in schizophrenia. Numerous scales have been developed to assess anticholinergic burden and yet, there is no consensus indicating...
5.
Chirokoff V, Berthoz S, Fatseas M, Misdrahi D, Dupuy M, Abdallah M, et al.
Transl Psychiatry
. 2024 Jun;
14(1):260.
PMID: 38897999
Functional inhibition is known to improve treatment outcomes in substance use disorder (SUD), potentially through craving management enabled by underlying cerebral integrity. Whereas treatment is challenged by a multitude of...
6.
Fernandes S, Brousse Y, Zendjidjian X, Cano D, Riedberger J, Llorca P, et al.
JMIR Ment Health
. 2024 May;
11:e49916.
PMID: 38753416
Background: The care environment significantly influences the experiences of patients with severe mental illness and the quality of their care. While a welcoming and stimulating environment enhances patient satisfaction and...
7.
Chirokoff V, Pohl K, Berthoz S, Fatseas M, Misdrahi D, Serre F, et al.
Addict Biol
. 2024 May;
29(5):e13400.
PMID: 38706091
Substance use disorders are characterized by inhibition deficits related to disrupted connectivity in white matter pathways, leading via interaction to difficulties in resisting substance use. By combining neuroimaging with smartphone-based...
8.
Chirokoff V, Dupuy M, Abdallah M, Fatseas M, Serre F, Auriacombe M, et al.
Addict Neurosci
. 2024 Feb;
9.
PMID: 38389954
Background: Patients treated for Substance Use Disorders exhibit highly fluctuating patterns of craving that could reveal novel prognostic markers of use. Accordingly, we 1) measured fluctuations within intensively repeated measures...
9.
Donde C, Coulon N, Turbe H, Andre M, Boyer L, Capdevielle D, et al.
Schizophr Res
. 2023 Dec;
264:105-112.
PMID: 38128341
Background: Childhood Attention-deficit/hyperactivity disorder (C-ADHD) is a neurodevelopmental disorder, associated with an increased risk of subsequent schizophrenia. The objective of the present study was to determine the prevalence of C-ADHD...
10.
Fond G, Yon D, Tran B, Mallet J, Urbach M, Leignier S, et al.
Front Public Health
. 2023 Nov;
11:1182441.
PMID: 38026279
Background: Schizophrenia has high socioeconomic impact among severe psychiatric disorders. Aims: To explore clinician-reported and patient-reported inequities between patients under the poverty threshold vs. the others. Method: 916 patients consecutively...